Trading Systems Reacting to (CHE) Volatility
This article from Stock Traders Daily discusses the volatility surrounding Chemed Corp (NYSE: CHE), noting a potential shift from positive near-term sentiment and a lack of clear price positioning signals. It highlights elevated downside risk due to the absence of long-term support signals. The report provides AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to manage CHE's volatility.
Chemed Corporation 8-K SEC Filing Summary for May 18, 2026 – Key Entity Information and Voting Results
Chemed Corporation (NYSE: CHE) held its annual meeting on May 18, 2026, where directors were re-elected and PricewaterhouseCoopers LLP was ratified as independent auditors. Notably, shareholders rejected a non-binding advisory vote on the executive compensation program, a rare occurrence that could signal shareholder dissatisfaction and potentially lead to changes in corporate governance or increased market volatility. Investors are advised to monitor the company's response to this significant outcome.
Press Release: Chemed Corporation Holds Annual Meeting of Stockholders; Board Declares Quarterly Dividend
Chemed Corporation held its annual meeting of stockholders, where shareholders re-elected five Class I directors and ratified the appointment of Deloitte & Touche LLP as independent auditors. The Board of Directors also declared a quarterly cash dividend of $0.38 per share, payable on June 3, 2026, to holders of record as of May 23, 2026. This dividend follows a 11.8% increase announced in January and continues Chemed's history of dividend payments.
Chemed stockholders elect board, ratify auditor, reject executive pay plan
Chemed Corporation stockholders held their annual meeting, electing all eight director nominees and ratifying PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2026. However, the proposal for the company's executive compensation program was not approved. This recent news follows Chemed's strong first-quarter 2026 earnings, which surpassed analyst estimates.
Chemed Investors Reject Executive Pay Amid Board Reelection
At its annual meeting, Chemed Corporation shareholders re-elected the full board of directors and ratified PricewaterhouseCoopers LLP as the independent accountants. However, investors voted against the executive compensation program, indicating dissatisfaction with management's pay practices. Despite this, Chemed's stock (CHE) received an "Outperform" score from TipRanks' AI Analyst, Spark, due to strong financial performance.
Chemed stockholders elect board, ratify auditor, reject executive pay plan
Chemed Corporation's stockholders elected all eight nominees to its board of directors and ratified PricewaterhouseCoopers LLP as the independent auditor for the fiscal year ending December 31, 2026. However, shareholders did not approve the company’s executive compensation program in a non-binding advisory vote. This news follows Chemed's strong first-quarter 2026 earnings, which surpassed analyst expectations for both EPS and revenue, leading RBC Capital to raise its price target for the company.
Chemed Corporation Holds Annual Meeting of Stockholders; Board Declares Quarterly Dividend
Chemed Corporation's stockholders elected nine directors and ratified PricewaterhouseCoopers LLP as independent accountants at their 2026 annual meeting, though a non-binding proposal on executive compensation was not approved. Following the meeting, the Board of Directors declared a quarterly cash dividend of 60 cents per share, marking the 220th consecutive dividend for the company. Chemed operates two wholly-owned subsidiaries, VITAS Healthcare and Roto-Rooter.
Chemed Corporation Holds Annual Meeting of Stockholders; Board Declares Quarterly Dividend
Chemed Corporation held its annual stockholders' meeting, electing nine directors and ratifying PricewaterhouseCoopers LLP as independent accountants. The board also declared a quarterly cash dividend of 60 cents per share, marking the 220th consecutive dividend for the company. The non-binding proposal on executive compensation was not approved by stockholders.
Chemed Corp stock (US1638321034): hospice and plumbing specialist draws investor focus after latest
Chemed Corp, parent company of VITAS Healthcare and Roto-Rooter, is drawing investor attention following its latest quarterly update. The company's dual business model, encompassing the defensive US healthcare market through hospice services and everyday residential and commercial plumbing services, provides diversified cash flow streams. Investors are focusing on trends in patient census, reimbursement rates for VITAS, and service call volumes for Roto-Rooter, while also considering regulatory risks and labor costs.
Chemed Corp stock (US1638321034): Presentation at RBC Healthcare Conference
Chemed Corp (NYSE: CHE) announced it will present at the 2026 RBC Global Healthcare Conference, highlighting its investor engagement. The company's shares are trading at $420.89 with a 0.3% gain, and it is recognized as a dividend contender with over a decade of increases. Chemed operates with two main segments: VITAS Healthcare (hospice and palliative care) and Roto-Rooter (plumbing services), appealing to investors seeking stability in defensive sectors.
Chemed Corporation to Present at the 2026 RBC Global Healthcare Conference
Chemed Corporation has announced its participation in the RBC Capital Markets Global Healthcare Conference on May 20, 2026, where it will deliver a presentation. The event will take place in New York City, and an audio webcast will be available on Chemed's website, with a replay accessible for 90 days. The company, headquartered in Cincinnati, operates two wholly-owned subsidiaries: VITAS Healthcare, a national hospice care provider, and Roto-Rooter, a leading provider of plumbing and drain cleaning services.
Chemed Corporation to Present at the 2026 RBC Global Healthcare Conference
Chemed Corporation announced it will present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 20, 2026, at 8:30 a.m. (ET) in New York City. An audio webcast of the presentation will be available on Chemed's website, with a replay accessible for 90 days. Chemed operates two subsidiaries: VITAS Healthcare, the largest provider of end-of-life hospice care, and Roto-Rooter, a leading provider of plumbing services.
Chemed Corporation to Present at the 2026 RBC Global Healthcare Conference
Chemed Corporation announced it will present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026, at 8:30 a.m. (ET). The presentation will be webcast live on Chemed's website and a replay will be available for 90 days. Chemed operates VITAS Healthcare, a hospice care provider, and Roto-Rooter, a plumbing and drain cleaning service.
Chemed Corporation to Present at the 2026 RBC Global Healthcare Conference
Chemed Corporation announced it will present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 20, 2026, at 8:30 a.m. ET in New York City. A live audio webcast will be available on Chemed's website, with a replay accessible for 90 days. Chemed operates VITAS Healthcare and Roto-Rooter.
C WorldWide Group Holding A S Invests $2.19 Million in Chemed Corporation $CHE
C WorldWide Group Holding A S recently invested $2.19 million in Chemed Corporation, acquiring 5,117 shares in the fourth quarter. Chemed reported strong quarterly earnings, beating estimates with $5.65 EPS and $657.5 million in revenue. The company also announced a quarterly dividend of $0.60, while insider activity included CEO Kevin J. Mcnamara selling 2,000 shares.
How Chemed Corp (CHE) Affects Rotational Strategy Timing
This article analyzes Chemed Corp (NYSE: CHE) using AI models, revealing mixed sentiment and a mid-channel oscillation pattern. It presents three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored to different risk profiles. The analysis highlights a significant 36.7:1 risk-reward short setup, targeting a 10.6% downside.
[144] CHEMED CORP SEC Filing
This article reports on a Form 144 SEC filing by CHEMED CORP (CHE), indicating a neutral impact and sentiment. The filing details the proposed sale of 70 shares of capital stock by an individual who acquired them on May 29, 2025, through executive compensation from the issuer. The sale, valued at $29,807, is set for May 8, 2026, via J.P. Morgan Securities LLC on the NYSE.
Chemed director Patrick P. Grace sells $25,546 in stock By Investing.com
Chemed director Patrick P. Grace sold 60 shares of CHEMED CORP (NYSE:CHE) stock for a total of $25,546 on May 8, 2026, according to a recent SEC filing. Despite the sale, the company, valued at $5.6 billion, is considered undervalued by InvestingPro analysis and has maintained dividend payments for 56 consecutive years. Chemed also reported strong first-quarter 2026 earnings, surpassing analyst expectations, which led RBC Capital to raise its price target.
Chemed Corp (CHE) director sells 60 shares at $425.78
Chemed Corp director Patrick P. Grace sold 60 shares of Chemed Capital Stock in an open-market transaction at an average price of $425.78 per share. After the sale, Grace directly owns 3,337 shares of the company. The transaction, filed on a Form 4, represented a small portion of his total holdings.
Chemed Corp stock (US1638321034): Home health and hospice growth continues to drive earnings
Chemed Corp reported strong quarterly results, with its VITAS hospice and Roto-Rooter home services segments showing revenue growth and improved operating margins. The company's diversified business model, catering to an aging population and essential home services, positions it well for stable earnings. This performance reflects investor confidence in Chemed's recurring revenue streams and resilience against economic fluctuations, despite potential regulatory and competitive risks in the healthcare sector.
CHE SEC Filings - Chemed Corp 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Chemed Corporation's (NYSE: CHE) SEC filings, including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms. It highlights how these filings offer insights into Chemed's subsidiaries, VITAS Healthcare and Roto-Rooter, detailing financial performance, regulatory impacts, and capital allocation. The platform also offers AI-powered summaries, impact scoring, and sentiment analysis for each filing, helping investors analyze key disclosures.
Chemed Corporation to Present at the Bank of America Securities Health Care Conference 2026
Chemed Corporation announced it will present at the Bank of America Securities 2026 Health Care Conference on Tuesday, May 12, 2026, at 3:00 PM (PDT). The presentation will be webcast live and accessible via the company's investor relations website, with a replay available for 90 days. Chemed Corporation operates VITAS Healthcare, a hospice care provider, and Roto-Rooter, a plumbing and drain cleaning service.
Chemed Corporation to Present at the Bank of America Securities Health Care Conference 2026
Chemed Corporation announced it will present at the Bank of America Securities 2026 Health Care Conference on May 12, 2026, at 3:00 PM (PDT). The presentation will be webcast live and accessible via the company's website. Chemed operates VITAS Healthcare, a hospice care provider, and Roto-Rooter, a plumbing services company.
Van Berkom & Associates Inc. Acquires 4,056 Shares of Chemed Corporation $CHE
Van Berkom & Associates Inc. increased its stake in Chemed Corporation by 2.4%, acquiring an additional 4,056 shares, bringing its total holding to 174,869 shares, valued at $74,819,000. Institutional investors collectively own 95.85% of Chemed, while company insiders hold about 3.33%. Chemed recently exceeded Q1 earnings expectations, reporting EPS of $5.65 against an estimated $5.30, and has a consensus "Hold" rating from analysts with an average price target of $501.50.
The company behind VITAS and Roto-Rooter presents in Las Vegas May 12
Chemed Corporation (NYSE:CHE), the parent company of VITAS Healthcare and Roto-Rooter, announced it will present at the Bank of America Securities 2026 Health Care Conference on May 12, 2026, at 3:00 PM PDT in Las Vegas. The presentation will be webcast live and a replay will be available for 90 days on Chemed's investor website. This announcement is part of Chemed's ongoing investor outreach, following recent positive financial news and strategic operational updates for its hospice and plumbing services subsidiaries.
Sadness This Mother's Day? VITAS® Healthcare Launches Free, Nationwide Mother's Day Grief Helpline
VITAS Healthcare has launched a free, nationwide Mother's Day Grief Helpline to provide support for those experiencing sadness or loss during this emotional time. The helpline aims to offer comfort and resources to individuals coping with grief on Mother's Day. This initiative highlights the importance of addressing emotional well-being during holidays that can be particularly challenging for those who have lost a mother or child.
Chemed Corporation to Present at the Bank of America Securities Health Care Conference 2026
Chemed Corporation announced that it will present at the Bank of America Securities 2026 Health Care Conference on Tuesday, May 12, 2026, at 3:00 PM (PDT). The presentation will be webcast live on Chemed's website and a replay will be available for 90 days. Chemed Corporation operates VITAS Healthcare, the largest provider of end-of-life hospice care, and Roto-Rooter, a leading provider of plumbing and drain cleaning services.
Chemed Corporation $CHE Shares Acquired by Mitsubishi UFJ Trust & Banking Corp
Mitsubishi UFJ Trust & Banking Corp significantly increased its stake in Chemed Corporation (NYSE:CHE) by 312% in Q4, acquiring an additional 4,746 shares, bringing its total to 6,267 shares valued at $2.68 million. While institutional ownership is high at 95.85%, insiders hold 3.33%, with CEO Kevin J. McNamara recently selling 2,000 shares. Analyst ratings are mixed, leading to an average "Hold" rating and a target price of $501.50, despite the company beating EPS estimates and issuing positive FY2026 guidance.
Chemed CEO Kevin McNamara sells $842,260 in Che stock
Chemed CEO Kevin J. McNamara sold 2,000 shares of the company's stock for $842,260 on May 1, 2026, with prices ranging from $418.99 to $424.95 per share. Following this transaction, McNamara directly holds 90,219 shares. This insider sale occurs as Chemed's stock, trading at $426.90, is considered undervalued by InvestingPro analysis, and the company recently reported strong Q1 2026 financial results, exceeding analyst expectations, which led RBC Capital to raise its price target.
Chemed (CHE) CEO Kevin McNamara sells 2,000 shares at $421.13 average
Chemed Corporation CEO Kevin J. McNamara sold 2,000 shares of Chemed Capital Stock in an open-market transaction. The shares were sold at a weighted average price of $421.13, with individual trades ranging from $418.99 to $424.95. Following this sale, McNamara directly holds 90,219 shares of Chemed stock.
Chemed (NYSE:CHE) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen upgraded Chemed (NYSE:CHE) stock from a "hold" to a "buy" rating, though the consensus among analysts remains a "Hold" with an average price target of $501.50. The company reported better-than-expected Q1 EPS of $5.65 and provided strong FY2026 guidance. This upgrade comes amidst mixed ratings from other research firms, with Chemed demonstrating solid financial performance and institutional interest.
Chemed Corporation (NYSE: CHE) affiliate files Form 144 to sell 1,000 shares
An affiliate of Chemed Corporation (NYSE: CHE) has filed a Form 144 with the SEC, indicating a proposed sale of 1,000 shares of common stock through Merrill Lynch with an entry dated May 1, 2026. The filing also details prior stock awards and exercises, including 682 shares on August 2, 2024, and 318 shares on October 30, 2023. Recent sales reported in the past three months for the same shareholder include transactions of 1,000, 1,000, and 1,500 shares on March 12, 2026, and March 27, 2026, by Kevin McNamara.
Kevin McNamara reports Common stock sales (CHE) on Form 144
Kevin J. McNamara has filed a Form 144, indicating proposed sales of Common Stock of CHE. The filing details multiple transactions from March 2026, totaling 3,500 shares with a combined value exceeding $1.3 million. Raymond James & Associates is listed as the broker involved in these sales.
Vanguard Capital Management (CHE) reports 744,055 shares, 5.40% stake
Vanguard Capital Management has reported a 5.40% stake in Chemed Corp, holding 744,055 shares as of March 31, 2026. This disclosure was made via a Schedule 13G SEC filing, indicating a passive investment approach. Vanguard retains sole dispositive power over all these shares and sole voting power over 107,985 shares.
(CHE) and the Role of Price-Sensitive Allocations
This article analyzes Chemed Corp (NYSE: CHE), noting strong near and mid-term sentiment but a weak long-term outlook. It identifies a mid-channel oscillation pattern and an exceptional 37.4:1 risk-reward short setup targeting a 10.9% downside with 0.3% risk. The analysis includes three institutional trading strategies (Position, Momentum Breakout, Risk Hedging) and multi-timeframe signal analysis, emphasizing real-time AI-generated signals for entry, exit, and risk management.
Chemed (NYSE:CHE) Raised to Hold at Zacks Research
Zacks Research has upgraded Chemed (NYSE:CHE) from a "strong sell" to a "hold" rating. This upgrade comes amidst a mixed analyst landscape, with other firms like Oppenheimer and Royal Bank of Canada also offering their ratings and price targets. Chemed recently reported strong quarterly earnings, beating analyst estimates, and has provided FY 2026 guidance.
VITAS posts strong earnings, revenue growth in 2026 Q1
VITAS Healthcare, the nation’s largest provider of hospice and palliative care services, reported stronger-than-expected earnings and admissions growth in Q1 2026, with net income up 4.4% and revenue increasing 3.1%. The company's parent, Chemed Corporation, also beat earnings and revenue forecasts, despite a slight decrease in overall profits. VITAS successfully navigated the Medicare cap billing limitation in Florida, which had negatively impacted revenue in 2025.
Abacus FCF Advisors LLC Acquires New Holdings in Chemed Corporation $CHE
Abacus FCF Advisors LLC has acquired a new position of 13,871 shares in Chemed Corporation, valued at approximately $5.94 million, while M&T Bank Corp significantly increased its stake. Chemed recently reported strong Q1 adjusted EPS of $5.65, beating estimates, and raised its FY2026 guidance to $24.00–$24.75, despite mixed operational results from its VITAS hospice and Roto-Rooter segments. The company also repurchased 500,000 shares and closed two franchise purchases.
CHE Q1 Deep Dive: VITAS Drives Growth, Roto-Rooter Adapts to Higher Marketing Costs
Chemed Corporation reported strong Q1 CY2026 results, exceeding revenue expectations, primarily driven by its VITAS hospice business. VITAS saw increased admissions and managed labor costs efficiently, while Roto-Rooter adapted to higher marketing expenses due to changes in digital search algorithms and faced weather-related disruptions. The company's outlook focuses on sustaining VITAS's growth through increased staffing and managing Roto-Rooter's evolving cost structure, alongside monitoring regulatory developments.
Impax Asset Management Group plc Trims Position in Chemed Corporation $CHE
Impax Asset Management Group plc reduced its stake in Chemed Corporation by 3.5% in Q4, selling 8,940 shares and now owning 244,242 shares valued at $104.5 million. Chemed reported strong Q1 adjusted EPS of $5.65, exceeding estimates, and raised its FY2026 guidance, though revenue growth was modest and its Roto-Rooter segment showed margin pressure. Analyst sentiment is mixed with several firms cutting price targets, and CEO Kevin J. McNamara recently sold 2,000 shares of the stock.
Full Transcript: Chemed Q1 2026 Earnings Call
Chemed Corporation reported strong Q1 2026 results, with its VITAS division exceeding expectations due to improved patient mix and controlled labor costs, leading to an upward revision of its full-year 2026 guidance. The Roto Rooter segment showed signs of improvement in core services despite increased marketing expenses and weather disruptions, and the company completed two strategic franchise acquisitions. Management remains confident in achieving sustainable growth through ongoing initiatives and market expansion.
Earnings call transcript: Chemed Q1 2026 earnings exceed forecasts, stock surges
Chemed Corporation reported robust Q1 2026 earnings, with EPS of $5.65 and revenue of $657.5 million, both surpassing analyst expectations. This led to a 13.59% surge in premarket trading. While VITAS Healthcare showed strong revenue and increased admissions, Roto-Rooter faced challenges with revenue declines in some segments and higher marketing costs due to Google algorithm changes and weather disruptions.
Copeland Capital Management LLC Sells 8,815 Shares of Chemed Corporation $CHE
Copeland Capital Management LLC reduced its stake in Chemed Corporation by 6.0% in the fourth quarter, selling 8,815 shares and retaining 137,551 shares valued at approximately $58.85 million. Despite this, Chemed reported strong Q1 results, beating EPS estimates, raising FY2026 guidance, and executing share repurchases and strategic acquisitions for its Roto-Rooter segment. Analysts maintain a "Hold" consensus with an average price target near $498, though some have downgraded the stock.
Chemed: Q1 Earnings Snapshot
Chemed Corp. (CHE) reported first-quarter net income of $66.3 million, or $4.84 per share, with adjusted earnings of $5.65 per share. The company, which operates Roto-Rooter and Vitas Healthcare, posted revenue of $657.5 million and expects full-year earnings between $24 and $24.75 per share.
Chemed reports Q1 2026: Revenue $657.5M, GAAP EPS $4.84, Adjusted EPS $5.65
Chemed reported strong first-quarter 2026 results with consolidated revenue of $657.5 million, GAAP diluted EPS of $4.84, and adjusted diluted EPS of $5.65. The company repurchased 500,000 shares for $197.7 million and raised its full-year adjusted EPS guidance to $24.00–$24.75, driven by improved VITAS performance and significant share repurchases. Both VITAS and Roto-Rooter segments showed key operational highlights, with VITAS experiencing revenue growth and Roto-Rooter making strategic acquisitions.
Chemed (NYSE: CHE) raises 2026 EPS guidance as VITAS outperforms, Roto-Rooter margins ease
Chemed Corporation has raised its full-year 2026 adjusted EPS guidance to $24.00–$24.75, up from its previous range, driven by stronger-than-anticipated performance from its VITAS Healthcare segment. Despite modest overall revenue growth in Q1 2026, the Roto-Rooter segment experienced a slight revenue decline and reduced margins due to increased marketing costs and weather disruptions. The company also repurchased 500,000 shares for $197.7 million and acquired two Roto-Rooter franchises for $20.6 million.
Chemed: Q1 Earnings Snapshot
Chemed Corp. (CHE) reported a net income of $66.3 million in its first quarter, with earnings adjusted for one-time gains and costs at $5.65 per share. The company, which operates Roto-Rooter and Vitas Healthcare, posted revenues of $657.5 million. Chemed anticipates full-year earnings to be between $24 and $24.75 per share.
Chemed Reports First-Quarter 2026 Results
Chemed Corporation reported its first-quarter 2026 financial results, with consolidated revenue increasing 1.6% to $657.5 million. The company increased its full-year guidance due to strong performance from its VITAS Healthcare segment and the repurchase of 500,000 shares. Roto-Rooter's revenue slightly declined, but the company made two strategic franchise acquisitions for $20.6 million.
Chemed earnings on deck as hospice, plumbing units face tests
Chemed Corp. is set to report its first-quarter earnings, with investors focused on stabilizing its hospice and plumbing units after a disappointing previous quarter. Analysts anticipate $5.34 EPS on $651 million revenue, reflecting ongoing pressures on its VITAS Healthcare and Roto-Rooter segments. The company's full-year guidance and ability to address industry headwinds will be key to its performance and investor confidence.
M&T Bank Corp Raises Stock Holdings in Chemed Corporation $CHE
M&T Bank Corp significantly increased its stake in Chemed Corporation by 10,291.1% in Q4, acquiring 85,107 shares to own a total of 85,934 shares valued at approximately $36.77 million. Despite Chemed missing Q4 earnings and revenue estimates, analysts maintain a "Hold" rating with a consensus price target of $498. The company's stock currently trades around $373.15, has a market cap of $5.45 billion, and a dividend yield of 0.6%.
